Heparin Calcium

drug
On this page

Also known as CalciparineEcasolvHeparin calcium saltHeparinum calcicumUniparin ca

Summary

Heparin Calcium (CHEMBL1201513) is an approved oligosaccharide; indicated across 2 conditions including habitual spontaneous abortion and immunoglobulin a vasculitis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Oligosaccharide
  • Indications: 2 conditions

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201513
NameHeparin Calcium
TypeOligosaccharide
Max phase4

Also known as: Calciparine, Ecasolv, Heparin calcium, Heparin calcium salt, Heparinum calcicum, Uniparin ca, HEPARIN CALCIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
habitual spontaneous abortion2MONDO:0006774EFO:1000954
immunoglobulin A vasculitis1MONDO:0019167EFO:1000965

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).